Food and Medication Administration seeking authorization to advertise Colchicine Tablets USP.
Actavis documents ANDA with FDA to advertise Colchicine Tablets USP Actavis plc today confirmed that it has filed an Abbreviated New Drug Application with the U.S best generic and branded medicines store . Food and Medication Administration seeking authorization to advertise Colchicine Tablets USP, 0.6 mg. Related StoriesHutchison MediPharma starts sulfatinib Phase I trial in USMylan announces U.S. Launch of generic AXERT tabletsImmune submits Bertilimumab IND program to FDA for treatment of Bullous Pemphigoid Takeda Pharmaceuticals U.S.A., Inc. Filed match against Actavis on February 27, 2014 in the U.S. District Court for the District of Delaware seeking to prevent Actavis from commercializing its ANDA product before the expiration of certain U.S.